Further characterization of ADAMTS-13 inactivation by thrombin by LAM, J K et al.
ORIGINAL ARTICLE
Further characterization of ADAMTS-13 inactivation by
thrombin
J. K. LAM, C. K. N. K. CHION, S. ZANARDELLI, D. A. LANE andJ. T. B. CRAWLEY
Department of Haematology, Imperial College London, London, UK
To cite this article: Lam JK, Chion CKNK, Zanardelli S, Lane DA, Crawley JTB. Further characterization of ADAMTS-13 inactivation by thrombin.
J Thromb Haemost 2007; 5: 1010–8.
Summary. Background: The multimeric size and platelet-
tethering function of von Willebrand factor (VWF) are
modulated by the plasma metalloprotease, a disintegrin and
metalloproteinase with a thrombospondin type 1 motif,
member 13 (ADAMTS-13). In vitro ADAMTS-13 is suscept-
ible to proteolytic inactivation by thrombin. Objectives: In this
study, we aimed to characterize the inactivation of ADAMTS-
13 by thrombin and to assess its physiological signiﬁ-
cance. Methods and results: By N-terminal sequencing of
cleavage products, and by mutagenesis, we identiﬁed the
principal thrombin cleavage sites in ADAMTS-13 as R257
and R1176. Using a library of 76 thrombin mutants, we
highlighted the functional importance of exosite I on thrombin
intheproteolysisofADAMTS-13.ProteolysisofADAMTS-13
by thrombin caused an 8-fold reduction in its aﬃnity for VWF
that contributed to its loss of VWF-cleaving function. Intrigu-
ingly, thrombin-cleaved ADAMTS-13 both bound and pro-
teolyzed a short recombinant VWF A2 domain substrate
(VWF115) normally. Following activation of coagulation in
normal plasma, endogenous ADAMTS-13, but not added
ADAMTS-13, appeared resistant to coagulation-induced frag-
mentation. An estimation of the Km for ADAMTS-13
proteolysis by thrombin was appreciably higher than the
physiological concentration of ADAMTS-13. This was corro-
borated by the comparatively low aﬃnity of ADAMTS-13 for
thrombin (KD95 nM). Conclusions: Together, our data suggest
that ADAMTS-13 is protected from rapid proteolytic inacti-
vationbythrombininnormalplasma.Whetherthisremainsthe
case under pathological situations involving elevated/sustained
generation of thrombin remains unclear.
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Introduction
von Willebrand factor (VWF) is a large, multimeric plasma
glycoprotein that is expressed by endothelial cells and mega-
karyocytes [1]. Multimers arise through C- and N-terminal
disulﬁde-bond formation [2]. This process generates ultra-
large multimers (UL-VWF) that can exceed 2 · 10
4 kDa.
Endothelial VWF is constitutively secreted, but also stored
within Weibel–Palade bodies, predominantly as UL-VWF [3].
This pool is released upon endothelial cell activation [4]. A wide
range of VWF species is found in normal plasma, differing only
in the number of component VWF units.
VWF mediates rapid adhesion of platelets at sites of vascular
injury. This occurs by the speciﬁc bridging of circulating
platelets and the injured vessel wall. The platelet-tethering
properties of VWF are dependent upon its multimeric size [5].
Larger multimers bind circulating platelets tighter, and also
more readily undergo conformational changes in response to
the rheological forces [6]. VWF multimers circulate in a
globular conformation that does not interact with platelets.
However, following vessel injury, globular VWF binds rapidly
and tightly to the exposed subendothelial collagen. The
increased shear forces exerted by the circulating blood cause
the bound globular VWF molecule to unravel [7]. This exposes
binding sites for glycoprotein Iba (a receptor present on the
surface of circulating platelets) in the VWF A1 domain that
leads to the local recruitment of platelets, and the formation of
a primary platelet plug [8].
VWF multimeric size/platelet-tethering function is modula-
ted by the plasma metalloprotease, a disintegrin and metallo-
proteinase with a thrombospondin type 1 motif, member 13
(ADAMTS-13), which cleaves VWF at a single site in the A2
domain [9,10]. This converts UL-VWF secreted by endothelial
cells into lower-molecular-weight forms with reduced adhesive
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glycoprotein [11]. The metalloprotease domain at the N-
terminus of ADAMTS-13 contains a highly conserved active
site responsible for VWF A2 domain proteolysis. The disinte-
grin-like domain and the ﬁrst thrombospondin-1 repeat
domain (TSP) precede the Cys-rich domain. The Spacer
domain is essential for full ADAMTS-13 activity and binds
to the C-terminal aspect of the VWF A2 domain [12,13]. This
domain links the Cys-rich region to seven consecutive TSP
repeats. Unlike other ADAMTS family members, ADAMTS-
13 has two C-terminal CUB domains. The ﬁrst CUB domain
may be involved in modulating ADAMTS-13 activity, or in
helping to attach ADAMTS-13 to the A3 domain of UL-VWF
strings under ﬂowing conditions [14,15]. With the exception of
the metalloprotease and Spacer domains, the precise role that
each ADAMTS-13 domain plays remains unclear. ADAMTS-
13 is expressed predominantly by the liver and secreted into the
blood as an active enzyme (plasma concentration of 5n M)
[16]. ADAMTS-13 is also expressed by endothelial cells in
culture [17,18].
How ADAMTS-13 activity is regulated has yet to be
deﬁned. We previously reported that ADAMTS-13 is suscept-
ible to proteolytic fragmentation by thrombin [and also factor
(F) Xa and plasmin], and that this ablates its VWF-cleaving
function [19]. Proteolysis might represent a mechanism by
which ADAMTS-13 function is locally modulated at sites of
vascular injury, thereby limiting VWF proteolysis and reducing
platelet embolization. To better understand both the mode
and the physiological signiﬁcance of this process, we have
characterized further the proteolysis and inactivation of
ADAMTS-13 by thrombin.
Materials and methods
Expression and puriﬁcation of ADAMTS-13
Wild-type (WT) recombinant ADAMTS-13 (rADAMTS-13)
with a C-terminal myc/His tag was expressed in HEK293 cells
and puriﬁed as previously described [19,20]. R257A and
R1176H ADAMTS-13 mutants were generated using Quik-
change site-directed mutagenesis, according to manufacturers
instructions (Stratagene, Amsterdam, The Netherlands), and
veriﬁed by sequencing. For transient transfection and expres-
sion, the pcDNA3.1/ADAMTS-13-myc/His expression vector
(or R257A and R1176H mutants) was transfected into 10 cm
dishes of 70% conﬂuent HEK293T cells using Lipofectamine
(Invitrogen, Paisley, UK), according to manufacturers instruc-
tions. Conditioned media were collected 3 days post-transfec-
tion. Cell debris was removed and samples dialyzed into 20 mM
Tris (pH 7.8). ADAMTS-13 concentrations were determined
using a speciﬁc ELISA [21].
Proteolysis of ADAMTS-13 by thrombin
To assess proteolysis in vitro, reactions containing rADA-
MTS-13 (or mutant), thrombin (Sigma, Poole, UK), 150 mM
NaCl, 5 mM CaCl2,2 0m M Tris (pH 7.8) were incubated at
37  C. Subsamples were removed at designated time-points,
and stopped with EDTA. The amount of thrombin and
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given for each experiment in the Results section and in the
ﬁgure legends. Proteolysis of ADAMTS-13 was assessed by
Western blotting under reducing conditions using either an
antimetalloprotease domain monoclonal antibody (mAb), an
anti-CUB domain mAb (both generously provided by Dr F.
Scheiﬂinger, Baxter, Vienna, Austria), or an anti-ADAMTS-
13 polyclonal antibody (pAb) generated and puriﬁed in our
laboratory [21]. To assess the contribution of surface residues
on thrombin in the proteolysis of ADAMTS-13, a library of
76 single surface residue thrombin point mutants was used
(kindly provided by Dr L. Leung, Stanford University, CA,
USA) [22]. All mutants were active-site titrated using S-2238,
as previously described [22], to ensure that the same speciﬁc
activity was used. WT thrombin (or mutant) was added to
each reaction, containing 250 nM ADAMTS-13, and incu-
bated for 0–2 h. Western blotting was then performed using
both the anti-CUB domain and antimetalloprotease domain
mAbs.
In reactions containing VWF or ﬁbrinogen, 50 nM ADAM-
TS-13 was preincubated at 37  C for 20 min with or without
500 nM plasma-derived VWF (gel puriﬁed from Haemate P,
and quantiﬁed as described previously [23]), or 7 lM ﬁbrinogen
(Quadratech, Surrey, UK). Thereafter, 100 nM thrombin was
added and incubated as above. Proteolysis was assessed using
the anti-ADAMTS-13 pAb or antimetalloprotease domain
mAb.
For N-terminal sequencing, 1 lM ADAMTS-13 was
incubated with 100 nM thrombin for 6 h and subjected to
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS–PAGE) on 16% acrylamide Tris-Tricine gels under
reducing conditions. Bands were excised and subjected to N-
terminal sequencing (Alta Bioscience, Birmingham, UK).
Potential thrombin cleavage sites were identiﬁed in silico
using PeptideCutter software (http://us.expasy.org/tools/pep-
tidecutter/).
Proteolysis of ADAMTS-13 in plasma
In plasma experiments, coagulation was initiated in citrated
normal human plasma, or plasma from aﬁbrinogenemic
patients (George King Biomedical, Overland Park, KS, USA)
by the addition of 8 pM lipidated tissue factor (Baxter),
Ca
2+,a n d4lM phospholipids (phosphatidylserine:phosphat-
idylcholine:phosphatidylethanolamine – 20:60:20; Avanti,
Alabaster, AL, USA), as previously described [19]. To
prevent clot formation and to allow Western blot analysis,
5m gm L
)1 Gly-Pro-Arg-Pro-amide (Sigma), which allows
ﬁbrinogen cleavage but prevents ﬁbrin polymerisation, was
included. After 30 min, samples were analyzed by Western
blotting using the anti-ADAMTS-13 pAb. Thrombin gen-
eration was monitored in parallel samples, as previously
described [19].
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Two ADAMTS-13 activity assays were used [with either
plasma-derived multimeric VWF or a recombinant bacterially
expressed A2 domain fragment (VWF115) as a substrate]
[19,20]. For competition experiments, ADAMTS-13 was
preincubated with or without 100 nM thrombin for 6 h at
37  C. A molar excess of hirudin (Calbiochem, Nottingham,
UK) was added to speciﬁcally inhibit thrombin [19]. Activity
assays containing either 6 nM ADAMTS-13, 60 nM thrombin-
cleaved ADAMTS-13, or a mixture containing 6 nM ADAM-
TS-13 and 60 nM thrombin-cleaved ADAMTS-13 were incu-
bated at 37  Cw i t h1 0n M VWF, 5 mM BaCl2,1 . 5M urea,
50 mM NaCl, 20 mM Tris (pH 7.8). Subsamples were removed
from 0 to 4 h, and stopped with EDTA. The proteolysis of
VWF by ADAMTS-13 was assessed by measuring the loss of
collagen binding function, as previously described [19,23].
For the VWF115 assay, 5 nM ADAMTS-13, or thrombin-
cleaved ADAMTS-13, was incubated at 37  C in reactions
containing 5 lMVWF115, 150 mMNaCl, 5 mMCaCl2,2 0m M
Tris (pH7.8). Subsamples were taken from 0 to 2 hand stopped
with EDTA. Proteolysis of VWF115 was assessed qualitatively
by SDS–PAGE on 16% acrylamide Tris-Tricine gels and
Coomassie staining. For kinetic analysis, reactions were set up
as above using 700 nM VWF115. Reactions were stopped, and
VWF115 proteolysis measured by high-performance liquid
chromatography. The catalytic efﬁciency of proteolysis was
determined as previously described [20].
ADAMTS-13 binding assays
To measure ADAMTS-13, or thrombin-cleaved ADAMTS-13
binding to multimeric VWF, VWF115 or thrombin, 30 nM
VWF, 140 nM VWF115 or 80 nM active site-blocked thrombin
was immobilized to the bottom of 96-well plates with 50 mM
sodium carbonate (pH9.6) overnight at 4  C. Wells were
washed with phosphate-buffered saline (PBS)/0.1% Tween-20,
and then blocked with 1% bovine serum albumin/PBS for 1 h.
One hundred microliter 0–1 lM ADAMTS-13 (or thrombin-
cleaved ADAMTS-13) was added to wells in triplicate and
incubated for 2 h. Wells were washed three times with PBS/
0.1% Tween-20 and bound ADAMTS-13 speciﬁcally detected
with 0.5 lgm L
)1 biotinylated anti-ADAMTS-13 pAb in
blocking buffer, and in turn detected with a streptavidin–
horseradish peroxidase conjugate (GE Healthcare, Bucking-
hamshire, UK). Bound conjugate was quantiﬁed by incubation
with o-phenylenediamine (Sigma) and then measuring the
absorbance at 492 nm.
Results
Identiﬁcation of thrombin cleavage sites in ADAMTS-13
ADAMTS-13 is rapidly proteolyzed and inactivated by
thrombin in a puriﬁed system [19]. To characterize this
inactivation, we aimed to delineate the precise sites in
ADAMTS-13 at which thrombin cleaves. There are at least
six thrombin cleavage sites in ADAMTS-13. Of these, two are
proteolyzed preferentially: one site located close to the carboxyl
end of the metalloprotease domain, and the other in between
the TSP8 domain and the CUB domains [19]. Analysis of the
primary amino acid sequence of ADAMTS-13 using Peptide-
Cutter software revealed the location of seven potential
thrombin cleavage sites: after R257 and R287 (metalloprotease
domain), R393 and R415 (TSP1), R910 (TSP5), R968 (TSP6),
and R1176 (in between TSP8 and CUB1) (Fig. 1A). Despite
these predictions, it remained unclear whether these were the
actual sites of proteolysis. We therefore separated ADAMTS-
13 proteolytic fragments by SDS–PAGE under reducing
conditions, as all proteolytic fragments remain covalently
associated by disulﬁde bonds with the exception of the C-
terminal CUB domain-containing fragment [19]. Bands of 28,
24 and 40 kDa were resolved and their N-termini determined
by Edman degradation. The 28 kDa fragment had an N-
terminal sequence of GILHLE, corresponding to the mature
ADAMTS-13 N-terminus (i.e. the start of the metalloprotease
domain). The 24 kDa fragment had the sequence AGLA,
representing a fragment generated by proteolysis after R257
A
BC
R287
R257
R257A WT
–+ –+ – + – +
R1176H WT
R1176
28 kDa
200 kDa
28 kDa
200 kDa
40 kDa
40 kDa
R393 R415 R910 R968
CUB
TSP-1 repeats
PR/AGLA PR/LLPGP
1
2
3
A
B
C
Fig. 1. Identiﬁcation of thrombin cleavage sites in ADAMTS-13. (A)
Diagram of ADAMTS-13 domain structure. Locations of predicted
thrombin cleavage sites after R287, R393, R415, R910 and R968 are
shown above. Thrombin cleavage sites determined by N-terminal
sequencing of cleavage fragments are shown below with the amino acid
sequence of the amino acids that ﬂank these sites. Single-letter amino acid
code is shown, P1 arginine is highlighted in bold, cleavage site is denoted
by (/). The location of the 28 and 40 kDa fragments detected in (B) and (C)
are highlighted. (B) Wild-type (WT) ADAMTS-13 and ADAMTS-
13(R257A) mutant were incubated with and without (+ and –) 10 nM
thrombin for 6 h and analyzed by Western blotting using an antimetal-
loprotease domain monoclonal antibody (mAb). Proteolysis after R257
was prevented by substitution of the P1 arginine to alanine, and resulted in
detection of alternative cleavage fragments 1, 2 and 3. (C) WT ADAMTS-
13 and ADAMTS-13(R1176H) mutant were incubated with and without
(+ and –) thrombin as in (B), and analyzed by Western blotting using an
anti-CUB mAb. Proteolysis after R1176 was signiﬁcantly inhibited by
substitution of the P1 arginine to histidine resulting in detection of
cleavage fragments A, B and C.
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most N-terminal cleavage site. The N-terminal sequence of the
40 kDa fragment was LLPGP. This corresponds to the most
C-terminal cleavage site, and arose through proteolysis after
R1176 (Fig. 1A). Other proteolytic fragments could not be
adequately resolved on the gel - either from each other or from
thrombin – in order to enable Edman degradation.
To further corroborate these ﬁndings we mutated the
predicted P1 (thrombin cleavage site) arginine residues in
ADAMTS-13 to prevent proteolysis at these sites. The region
surrounding R257 exhibits no homology amongst ADAMTS
family members, suggesting that this residue does not fulﬁll a
conserved structural role. Consequently, R257 was mutated to
alanine. R1176 was mutated to histidine to preserve the basic
nature of this amino acid. Both mutants were expressed/
secreted normally, and exhibited normal activity (data not
shown), suggesting that the substitutions did not signiﬁcantly
inﬂuence either the structure or the function of ADAMTS-13.
Incubation of these mutants with thrombin conﬁrmed R257
and R1176 as the two favored P1 cleavage site residues. After
proteolysis of WT ADAMTS-13 with 10 nM thrombin for 6 h,
no full-length ADAMTS-13 was detected by Western blotting
using an antimetalloprotease domain mAb. Instead, only a
single 28 kDa proteolytic fragment was observed. However,
whereas similar treatment of ADAMTS-13(R257A) demon-
strated a comparable loss of full-length ADAMTS-13, a
mixture of metalloprotease domain-containing fragments with
molecular masses greater than 28 kDa were detected (frag-
ments 1, 2 and 3: 30, 40 and 45 kDa, respectively),
indicating that proteolysis after R257 had been prevented
(Fig. 1B). Fragments 1, 2 and 3 possibly represent cleavage
products arising from proteolysis after the predicted/less-
favored R287, R393 and R415 sites, respectively. The detection
of a mixture of fragments also conﬁrmed that proteolysis after
R257 occurs more rapidly than at these other sites.
Analogous analysis of ADAMTS-13(R1176H) was per-
formed except that fragmentation was analyzed with an anti-
CUB mAb in order to more accurately monitor proteolysis
at this site. Similar to before, thrombin treatment of
ADAMTS-13 resulted in complete disappearance of full-
length ADAMTS-13 when detected with this mAb (Fig. 1C).
The only cleavage product detected was the 40 kDa CUB
domain-containing fragment. Proteolysis of ADAMTS-
13(R1176H) revealed a mixture of cleavage fragments
(fragments A, B and C: 40, 70 and 80 kDa, respect-
ively). Although thrombin speciﬁcally cleaves after certain
arginine (or lysine) residues, it is also capable of doing so
after histidine, albeit at an appreciably reduced (approxi-
mately one hundred sixtyfold) rate [24]. Fragment A most
likely represents the product of proteolysis after the R1176H
substitution. Fragments B and C are potentially fragments
arising from cleavage after R968 and R910, respectively. The
lack of information about the sites/extent of glycosylation in
ADAMTS-13 makes it difﬁcult to accurately predict the sites
of proteolysis that generate fragments 1, 2, 3, B and C based
on their molecular mass.
Identiﬁcation of thrombin exosite I residues important for
proteolysis of ADAMTS-13
To determine how thrombin interacts with ADAMTS-13,
we used a library of 76 thrombin variants that contained
single (predominantly charged) residue substitutions to
alanine of surface-exposed amino acids [22]. Proteolysis of
ADAMTS-13 by WT thrombin, or thrombin mutants, was
assessed by Western blot analysis using the anti-CUB mAb.
Under these conditions, the complete disappearance of full-
length ADAMTS-13 occurred after 2 h with WT thrombin.
Of all the thrombin mutants tested, only those with
substitutions located in exosite I of thrombin exhibited a
reduced propensity to cleave ADAMTS-13, as seen by the
presence of uncleaved ADAMTS-13 after 2-h incubation
with these variants (Fig. 2A; not all variants tested are
shown). Results were conﬁrmed by analysis using the
antimetalloprotease domain mAb (not shown). The throm-
bin variants with reduced ADAMTS-13-cleaving function
contained substitutions at K36, R67, H71, R73, T74, R75,
Y76, R77 and K81 (chymotrypsin numbering). These
residues are broadly similar to the exosite I residues in
thrombin that are important in the binding of thrombo-
modulin (TM; Fig. 2B,C) [22].
200 kDa
40 kDa
Thrombin mutants
Active
site
Active
site
ADAMTS13
ADAMTS-13
WT
R35A
R67A
R73A
R75A
R77A
R109A
R110A
K149A
H71A
T74A
Y76A
K36A
K70A
K81A
TM
A
BC
Fig. 2. Proteolysis of ADAMTS-13 by thrombin mutants. (A)
ADAMTS-13 was incubated with 100 nM of wild-type (WT) thrombin or
thrombin mutants carrying substitutions in surface-exposed residues.
After 2 h, ADAMTS-13 fragmentation by each diﬀerent thrombin variant
was assessed by Western blotting using an anti-CUB domain monoclonal
antibody. By comparison with WT thrombin the variants with substitu-
tions at K36, R67, H71, R73, T74, R75, Y76, R77 and K81 (chymotrypsin
numbering) exhibited reduced ability to cleave ADAMTS-13. Space-ﬁll
model of thrombin is shown. The active site cleft is highlighted. Those
residues shown in grey were determined to be important for proteolysis of
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location of these amino acids is very similar to those previously
demonstrated to be important for binding thrombomodulin (C).
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VWF, but with reduced afﬁnity
Althoughproteolysisof ADAMTS-13 by thrombinprevents its
ability to cleave VWF, how this inactivation occurs was
uncertain. To examine this, the ability of thrombin-cleaved
ADAMTS-13 to compete with ADAMTS-13 for VWF was
tested. As expected, ADAMTS-13 (6 nM) reduced the collagen-
binding function of VWF over time, whereas a 10-fold
increased amount of thrombin-cleaved ADAMTS-13 (60 nM)
was unable to do so (Fig. 3A). However, when 6 nM ADAM-
TS-13 was mixed with 60 nM thrombin-treated ADAMTS-13
(containinganexcessofhirudintoinhibit thrombin),therateof
loss of collagen-binding function was reduced when compared
with 6 nM ADAMTS-13 alone. This demonstrated that
proteolyzed ADAMTS-13 could block the proteolysis of
VWF by uncleaved ADAMTS-13, and suggests that ADAM-
TS-13 retains some VWF-binding function after thrombin
cleavage.
Thebindingofthrombin-cleavedADAMTS-13toVWFwas
analyzed using an equilibrium plate binding assay (Fig. 3B).
ADAMTS-13 bound immobilized VWF with high afﬁnity (KD
6n M), similar to previous estimates [25]. Although proteolyzed
ADAMTS-13 bound VWF with the same capacity, it did so
with approximately eightfold reduced afﬁnity (KD 45 nM).
ADAMTS-13 proteolyzed by thrombin remains fully activated
against VWF115
To examine the inactivation of ADAMTS-13 by thrombin
kinetically, we employed a previously characterized assay using
a recombinant A2 domain fragment, VWF115 [20]. Substrate
proteolysis was ﬁrst visualized by SDS–PAGE and Coomassie
staining (Fig. 4A). Surprisingly, thrombin-cleaved ADAMTS-
13 generated VWF115 cleavage products at a similar rate to
ADAMTS-13. However, a major difference between the
VWF115 and the multimeric VWF activity assays is the
presence of urea. To ensure that it was not the denaturant that
inactivated proteolyzed ADAMTS-13, we examined VWF115
proteolysisinthepresenceandabsenceof1.5 Murea.Thesedata
demonstrated that the ability of thrombin-cleaved ADAMTS-
13 to proteolyze VWF115 was not inﬂuenced by these mild
denaturing conditions (data not shown). Kinetic analysis of
VWF115 cleavage revealed that the catalytic efﬁciency of
cleavage(kcat/Km)forbothADAMTS-13andthrombin-cleaved
ADAMTS-13 (8 · 10
4
M
)1 s
)1and 11 · 10
4
M
)1 s
)1, respect-
ively) werevery similar to previousdata derivedfor ADAMTS-
13 [20] (Fig. 4B). A binding assay using immobilized VWF115
corroborated theseresultsby demonstrating that both ADAM-
TS-13 and thrombin-cleaved ADAMTS-13 bound VWF115
with equally high afﬁnity (KD 18 nM) (Fig. 4C). Together,
these data demonstrate that whereas thrombin proteolysis
inhibits the ability of ADAMTS-13 to cleave multimeric VWF,
it has no effect upon its ability to cleave short substrates. Thus,
despite the presence of a cleavage site within the ADAMTS-13
metalloprotease domain, rather surprisingly it appears that this
domain remains fully functional after proteolysis by thrombin.
Proteolysis of endogenous ADAMTS-13 by thrombin does
not occur in plasma
In an earlier study, we examined the proteolysis of ADAMTS-
13 following activation of coagulation in plasma [19]. However,
the relatively low afﬁnity of the available antibodies did not
allow detection of endogenous ADAMTS-13 in plasma.
Consequently, we were obliged to supplement normal plasma
with rADAMTS-13 in order to enable its detection. Using
more sensitive anti-ADAMTS-13 pAb, we now examined the
inﬂuence of coagulation upon endogenous ADAMTS-13.
Following initiation of coagulation in normal human plasma,
we detected no change in the intensity of the full-length
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Fig. 3. ADAMTS-13 proteolyzed by thrombin has reduced aﬃnity for
von Willebrand factor (VWF). (A) 6 nM ADAMTS-13, 60 nM thrombin-
cleaved ADAMTS-13 (ADAMTS-13/FIIa) or 60 nM thrombin-cleaved
ADAMTS-13/6 nM ADAMTS-13 (10:1 mix) was incubated with 10 nM
puriﬁed plasma-derived VWF in the presence of 1.5 M urea and 5 mM
BaCl2. At time-points (0–4 h) subsamples were stopped with EDTA and
VWF function measured using a collagen-binding assay (CBA). Changes
in CBA are represented as % original CBA at 0 h. A 10-fold molar excess
of proteolyzed ADAMTS-13 partially competed with ADAMTS-13 for
VWF. (B) The aﬃnity of ADAMTS-13 and thrombin-cleaved ADAMTS-
13 for puriﬁed plasma-derived VWF was measured by plate assay. 30 nM
VWF was immobilized to microtiter wells, and incubated with varying
concentrations of ADAMTS-13 or thrombin-cleaved ADAMTS-13
(ADAMTS-13/FIIa), as in Materials and methods. A high-aﬃnity inter-
action between ADAMTS-13 and VWF was determined (KD 6n M),
whereas this was appreciably reduced for ADAMTS-13/FIIa
(KD 45 nM).
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suggested that whereas rADAMTS-13 is efﬁciently cleaved by
thrombin in vitro, endogenous plasma ADAMTS-13 is in some
way protected from this proteolysis.
To rationalize this observation, we postulated that at normal
physiological ADAMTS-13 concentrations (5n M), other
components of plasma might inﬂuence its proteolysis. First, we
hypothesized that the binding of VWF to ADAMTS-13 might
protect it from thrombin. To test this we preincubated
ADAMTS-13 with and without a 10-fold molar excess of
puriﬁed multimeric VWF (approximate physiological ratio)
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Fig. 4. Proteolysis of ADAMTS-13 by thrombin does not inﬂuence the
cleavage of, or binding to, VWF115. (A) 5 nM ADAMTS-13 or thrombin-
cleaved ADAMTS-13 (ADAMTS-13/FIIa) was incubated at 37  Cw i t h
5 lM VWF115, 150 mM NaCl, 5 mM CaCl2,2 0m M Tris (pH7.8). Sub-
samples were stopped with EDTA (0–2 h) and analyzed by sodium do-
decylsulfate polyacrylamide gel electrophoresis and Coomassie staining.
Proteolysis of VWF115 was visualized by the disappearance of a 16.9 kDa
band and the appearance of 10 kDa and 6.9 kDa cleavage products. (B)
Kinetic analysis of VWF115 proteolysis, as in (A) except using 700 nM
VWF115. Proteolysis of VWF115 was quantiﬁed by high-performance
liquid chromatography, and represented graphically. The catalytic eﬃ-
ciency for VWF115 proteolysis was derived from ﬁtted data for both
ADAMTS-13 and ADAMTS-13/FIIa (8 · 10
4
M
)1 s
)1 and
11 · 10
4
M
)1 s
)1, respectively). (C) The aﬃnity of ADAMTS-13 and
thrombin-cleaved ADAMTS-13 for VWF115 was measured by plate as-
say. 140 nM VWF115 was immobilized to microtiter wells, and incubated
with varying concentrations of ADAMTS-13 or thrombin-cleaved AD-
AMTS-13 (ADAMTS-13/FIIa), as in Materials and methods. A similar
high-aﬃnity interaction was determined (KD 20 nM) for both ADAM-
TS-13 and ADAMTS-13/FIIa with VWF115.
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Fig. 5. ADAMTS-13 is not eﬃciently proteolyzed by thrombin in
plasma. (A) Endogenous ADAMTS-13 was detected in plasma by West-
ern blotting using an anti-ADAMTS-13 polyclonal antibody (pAb). No
change in the intensity of this band was observed 30 min after initiation of
coagulation. Conversely, multiple cleavage products were generated when
100 nM recombinant ADAMTS-13 (rADAMTS-13) was incubated with
100 nM thrombin for 30 min and analyzed in the same way. (B) 50 nM
rADAMTS-13 was incubated with 100 nM thrombin in the presence and
absence of 500 nM von Willebrand factor. ADAMTS-13 fragmentation
was analyzed from 0–90 min by Western blotting with an anti-ADAMTS-
13 pAb. (C) 100 nM rADAMTS-13 was incubated with thrombin in the
presence and absence of 7 lM human ﬁbrinogen (Fbn). ADAMTS-13
fragmentation was analyzed from 0–90 min by Western blotting with an
antimetalloprotease domain monoclonal antibody. (D) Endogenous
plasma ADAMTS-13 was detected in normal plasma and plasma from
aﬁbrinogenemic patients (Fbn-deﬁcient) as in (A). No change in the
intensity of the ADAMTS-13 band was observed 30 min after initiation of
coagulation in either plasma. (E) 5–160 nM rADAMTS-13 was incubated
with 25 nM thrombin for 60 min and thereafter ADAMTS-13 fragmen-
tation was analyzed as in (A). ADAMTS-13 prior to thrombin incubation
(0¢) is shown. For each concentration, the same amount of ADAMTS-13
was used for Western blotting. (F) The aﬃnity of ADAMTS-13 for
thrombin was measured by plate assay. 80 nM active site blocked
thrombin was immobilized to microtiter wells, and incubated with varying
concentrations of rADAMTS-13, as in Materials and methods. A KD
95 nM was determined.
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revealed no difference in the rate of ADAMTS-13 cleavage in
the presence/absence of VWF (Fig. 5B), indicating that once
bound to VWF, ADAMTS-13 remains equally susceptible to
thrombin cleavage in vitro.
We next examined whether other thrombin substrates might
impair the ability of thrombin to proteolyze ADAMTS-13 in
plasma. Fibrinogen is the most abundant thrombin substrate in
plasma. Incubation of ADAMTS-13 with thrombin in both the
presence and absence of 7 lM ﬁbrinogen revealed that appre-
ciable, if not complete, competition occurred. Fibrinogen
reduced the rate at which ADAMTS-13 was proteolyzed by
thrombin (Fig. 5C), consistent with their similar dependence
upon exosite I of thrombin (Fig. 2). To ascertain whether this
accounted for the lack of proteolysis of endogenous ADAM-
TS-13 in plasma, we initiated coagulation in plasma from
aﬁbrinogenemic patients (containing less than 1% normal
ﬁbrinogen levels), and examined ADAMTS-13 proteolysis as
before (Fig. 5D). However, despite the near absence of
ﬁbrinogen, the intensity of the endogenous full-length AD-
AMTS-13 band remained unaltered after 30 min.
The afﬁnity of thrombin for ADAMTS-13
As plasma ADAMTS-13 remained unaffected by coagulation,
even in the absence of ﬁbrinogen, we explored the effect of
ADAMTS-13 concentration upon its initial rate of proteolysis
by thrombin. To do this qualitatively, we incubated 5–160 nM
ADAMTS-13 with 25 nM thrombin for 60 min, and thereafter
assessed proteolysis using the anti-ADAMTS-13 pAb. For
each concentration, the same amount of ADAMTS-13 was
loaded for blotting. This ensured that the intensity of
ADAMTS-13 fragments observed was proportional to their
relative rates of proteolysis. ADAMTS-13 cleavage increased
with its concentration (Fig. 5E). This observation indicated
that the Km for this reaction must appreciably exceed the
plasma concentration of ADAMTS-13 (5 nM). This contention
was further supported when the afﬁnity of ADAMTS-13 for
thrombin was measured using an equilibrium plate binding
assay (Fig. 5F). We determined a KD of 95 nM –n e a r l y2 0
times greater than the plasma concentration of ADAMTS-13.
These data suggest that under normal physiological circum-
stances, ADAMTS-13 may be protected from proteolysis by
the comparatively low afﬁnity of thrombin for the metallo-
protease.
Discussion
ADAMTS-13 is susceptible to proteolytic inactivation by
thrombin (and certain other serine proteases) in vitro [19,26].
Physiologically, thrombin is generated rapidly, and at high
local concentrations during the normal hemostatic response. In
these locations, thrombin might readily encounter and so also
proteolyze ADAMTS-13 in vivo. Consequently, we endeav-
ored to characterize (i) the sites of proteolysis in ADAMTS-13
by thrombin, (ii) how thrombin recognizes ADAMTS-13, (iii)
the mode of its inactivation, and (iv) the physiological
signiﬁcance of such proteolysis.
Thrombin proteolyzes ADAMTS-13 at six or seven sites. Of
these, the most N-terminal and C-terminal sites are cleaved
preferentially [19]. N-terminal sequencing of cleavage frag-
ments demonstrated that the P1 residues of these favored sites
correspond to R257 and R1176. This was further conﬁrmed
when these residues were mutated to prevent/inhibit thrombin-
mediated cleavage. Although we were unable to speciﬁcally
identify the other, less-favored thrombin cleavage sites, they
could be predicted by primary sequence analysis. R287 (at the
end of the metalloproteasedomain) appears to besusceptible to
proteolysis, but this site is cleaved many times slower than
R257. The other predicted sites at R393, R415, R910 and R968
are located in positions in accordance with our previous
estimates [19]. As these sites were cleaved appreciably slower
than those at R257 and R1176, their likely signiﬁcance with
regard to the physiological inhibition of ADAMTS-13 is
uncertain. With the exception of the C-terminal CUB domains,
all proteolytic fragments remained covalently associated after
thrombin cleavage through disulﬁde bonds.
In order to more accurately establish how thrombin
recognizes and cleaves ADAMTS-13, we employed a library
of thrombin variants. Previously, we reported the ability
of soluble TM (and not heparin) to inhibit proteolysis of
ADAMTS-13 by thrombin, suggesting the importance
of exosite I (and not exosite II) on thrombin in this reaction
[19]. Thrombin interacts with its different substrates and
cofactors via these two charged exosites [27]. As only variants
carrying substitutions inexositeI (verysimilartothoserequired
for binding to TM [22]) exhibited impaired ADAMTS-13
cleavage, the functional importance of this region in ADAM-
TS-13 proteolysis was clearly demonstrated. All exosite II
variants tested cleaved ADAMTS-13 normally.
We found that thrombin-cleaved ADAMTS-13 still bound
VWF, but with 8-fold reduced afﬁnity (KD 45 nM).
Reduced binding would clearly compromise the ability of
ADAMTS-13 to cleave VWF. However, it is likely that there
are additional reasons for the inactivation of thrombin-cleaved
ADAMTS-13, as reactions containing 10-fold higher concen-
trations of thrombin-cleaved ADAMTS-13 were devoid of any
detectable VWF-cleaving function. Proteolysis of ADAMTS-
13 by thrombin after R1176 is predicted to result in the removal
of the C-terminal CUB domains from the rest of the molecule.
However, the loss of the CUB domains is by itself perhaps
unlikely to inactivate ADAMTS-13, as truncated variants
lacking these domains have previously been shown to retain
VWF-cleaving activity [28–31]. The inﬂuence of cleavage after
R257 could not be predicted, but naturally because of its
location could potentially disrupt the function of the metallo-
protease domain.
With a view to measuring the rate at which ADAMTS-13
was inactivated by thrombin, we performed ADAMTS-13
activity assays using VWF115, which enabled kinetic analysis
of proteolysis [20]. Intriguingly, we found that thrombin-
cleaved ADAMTS-13 remained fully active against this
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raises several interesting issues. Firstly, this demonstrates that
despite proteolysis at R257, the metalloprotease domain clearly
remains functional. Secondly, this highlights that there are
fundamental differences between the ADAMTS-13 activity
assays that employ multimeric VWF to those that use A2
domain fragments as a substrate. Very possibly, thrombin
cleavage ablates a functionality of ADAMTS-13 that is
essential for proteolysis of multimeric VWF but that is not
required for cleavage of short substrates. Consistent with this
was our ﬁnding that thrombin-cleaved ADAMTS-13 bound
normally to VWF115, but exhibited an 8-fold reduction in
afﬁnity for multimeric VWF. It therefore seems likely that there
are additional ADAMTS-13-binding sites outside the A2
domain that are important to its ability to proteolyze VWF. In
light of these data, analysis of ADAMTS-13 activity in plasma
samples using short A2 domain fragments should be carried
out cautiously, as results might not necessarily accurately
reﬂect the true VWF-cleaving function of ADAMTS-13 in
those instances where ADAMTS-13 proteolysis may have
occurred.
Examining the possible proteolysis of ADAMTS-13 by
thrombin physiologically during normal hemostasis is prob-
lematic. As cleavage might be predicted to occur only locally
at sites of vessel injury, this would be unlikely to have a
detectable effect upon ADAMTS-13 systemically. Conse-
quently, we were limited to the analysis of ADAMTS-13
proteolysis in plasma ex vivo. Previously, we observed
ADAMTS-13 proteolysis following initiation of coagulation
in plasma, but only when rADAMTS-13 was ﬁrst added to
enable its detection [19]. In the experiments reported here, we
could see no clear evidence for fragmentation of endogenous
ADAMTS-13. The major reason for this was not because of
its protection by VWF, or because of competition with other
substrates (such as ﬁbrinogen) for thrombin, but rather
because of the comparatively low afﬁnity of thrombin for
ADAMTS-13 (KD 95 nM). The high KD and Km for this
reaction very possibly protects ADAMTS-13 from rapid
proteolysis in plasma, and is consistent with the observed
presence of unproteolyzed ADAMTS-13 in serum. That
aside, it must be considered that the local concentrations of
ADAMTS-13 at sites of vessel damage are likely to be
elevated, as VWF is recruited to the injured region.
Consequently, whether the plasma experiments monitoring
ADAMTS-13 fragmentation are a fair representation of what
may happen to ADAMTS-13 physiologically at the site of
vessel injury remain uncertain.
Despite our ﬁndings, it is clear that ADAMTS-13 is
susceptible to proteolysis in vivo. This is particularly evident
in patients with sepsis-induced disseminated intravascular
coagulation (DIC) [26]. It remains unclear, however, which
enzyme(s) is responsible for the observed fragmentation of
ADAMTS-13. It is conceivable that the elevated and
systemic generation of thrombin that occurs during DIC
could cause appreciable proteolysis of ADAMTS-13. The
proteolytic inactivation of ADAMTS-13 would potentially
lead to reduced VWF processing and high concentrations of
UL-VWF that could in turn contribute to the pathogenesis
of DIC. The identiﬁcation of the sites of thrombin proteo-
lysis in ADAMTS-13 might be useful in determining whether
t h e s es a m es i t e sa r ec l e a v e din vivo,a n di nt u r na i di nt h e
identiﬁcation of the enzyme(s) responsible for its physio-
logical fragmentation.
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